{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-228399","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.640089+00:00","generated_at":"2026-05-31T00:50:13.375232+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vor Bio appoints Han Choi as CFO, effective Sept 30, 2024","bullets":["Han Choi, M.D., LL.M., named CFO; previously Principal at Oracle Investment Management for over 20 years.","Base salary of $464,000 per year and target annual bonus of 40% of base salary.","Granted stock option for 400,000 shares, vesting over 4 years (1/4 after 1 year, then monthly).","Choi brings experience in healthcare investment, business development, and capital markets strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-228399","json":"https://secwatch.observer/filing/0001193125-24-228399.json","markdown":"https://secwatch.observer/filing/0001193125-24-228399.md","text":"https://secwatch.observer/filing/0001193125-24-228399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524228399/0001193125-24-228399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524228399/d829992d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:50:13.375232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c486e59eaa","claim":"Han Choi was appointed as Chief Financial Officer at Vor Biopharma Inc..","evidence_excerpt":"On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524228399/0001193125-24-228399-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}